RAPT Therapeutics Inc. (RAPT)
RAPT Therapeutics Statistics
Share Statistics
RAPT Therapeutics has 132.01M shares outstanding. The number of shares has increased by 278.21% in one year.
Shares Outstanding | 132.01M |
Shares Change (YoY) | 278.21% |
Shares Change (QoQ) | 277.61% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 68.9M |
Failed to Deliver (FTD) Shares | 4 |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 2.64M, so 2% of the outstanding shares have been sold short.
Short Interest | 2.64M |
Short % of Shares Out | 2% |
Short % of Float | 3.27% |
Short Ratio (days to cover) | 0.29 |
Valuation Ratios
The PE ratio is -0.5 and the forward PE ratio is -0.57. RAPT Therapeutics's PEG ratio is -0.11.
PE Ratio | -0.5 |
Forward PE | -0.57 |
PS Ratio | 0 |
Forward PS | 4 |
PB Ratio | 0.34 |
P/FCF Ratio | -0.77 |
PEG Ratio | -0.11 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for RAPT Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.87, with a Debt / Equity ratio of 0.02.
Current Ratio | 4.87 |
Quick Ratio | 4.87 |
Debt / Equity | 0.02 |
Debt / EBITDA | -0.03 |
Debt / FCF | -0.05 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.91M |
Employee Count | 68 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.14% in the last 52 weeks. The beta is -0.29, so RAPT Therapeutics's price volatility has been lower than the market average.
Beta | -0.29 |
52-Week Price Change | -86.14% |
50-Day Moving Average | 1.19 |
200-Day Moving Average | 1.84 |
Relative Strength Index (RSI) | 42.58 |
Average Volume (20 Days) | 862.24K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -136.1M |
Net Income | -129.87M |
EBITDA | -136.1M |
EBIT | n/a |
Earnings Per Share (EPS) | -3.19 |
Balance Sheet
The company has 169.74M in cash and 4.49M in debt, giving a net cash position of 165.24M.
Cash & Cash Equivalents | 169.74M |
Total Debt | 4.49M |
Net Cash | 165.24M |
Retained Earnings | -614.55M |
Total Assets | 240.32M |
Working Capital | 186.88M |
Cash Flow
In the last 12 months, operating cash flow was -83.3M and capital expenditures -122K, giving a free cash flow of -83.42M.
Operating Cash Flow | -83.3M |
Capital Expenditures | -122K |
Free Cash Flow | -83.42M |
FCF Per Share | -2.05 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RAPT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for RAPT is $4, which is 260.4% higher than the current price. The consensus rating is "Hold".
Price Target | $4 |
Price Target Difference | 260.4% |
Analyst Consensus | Hold |
Analyst Count | 7 |
Scores
Altman Z-Score | -2.66 |
Piotroski F-Score | 1 |